Meclizine is primarily an antihistamine, but it does have anticholinergic properties. It’s classified as a first-generation H1 antihistamine, meaning its main job is blocking histamine receptors. However, it also blocks acetylcholine signaling in the brain, which gives it a secondary anticholinergic effect. This dual action is actually what makes it useful for both motion sickness and vertigo.
How Meclizine Works on Two Receptor Systems
Meclizine’s primary target is the H1 histamine receptor. By blocking this receptor, it reduces the nausea, dizziness, and vomiting associated with motion sickness. But meclizine also acts on the cholinergic system in the brain, interfering with acetylcholine, a chemical messenger involved in balance signals, gut motility, and many other functions. This combination of histamine blocking and acetylcholine blocking is what gives meclizine its ability to suppress nausea and calm the vestibular system (the inner-ear structures responsible for balance).
That said, meclizine’s anticholinergic activity is relatively weak compared to dedicated anticholinergic drugs. In receptor-binding studies, meclizine showed low affinity for muscarinic receptors, with binding values in the range of 3,600 to 30,000 nM. For context, the lower that number, the more tightly a drug binds to a receptor. Scopolamine, a true anticholinergic used for motion sickness, binds far more tightly. In a head-to-head trial, transdermal scopolamine provided better motion sickness protection than oral meclizine, and scopolamine also caused more dry mouth, a hallmark of stronger anticholinergic activity.
Anticholinergic Side Effects to Expect
Even though meclizine’s anticholinergic activity is mild, it’s still enough to cause side effects you’d associate with that class of drugs. Drowsiness is the most common, since blocking both histamine and acetylcholine in the brain has a sedating effect. Dry mouth is another frequent complaint. Some people also experience blurred vision, constipation, or difficulty urinating, all classic signs that a drug is interfering with acetylcholine signaling.
Because of these effects, the FDA labeling for meclizine (brand name Antivert) specifically warns that it should be used with caution if you have glaucoma, asthma, or an enlarged prostate. These are conditions where reduced acetylcholine activity can worsen symptoms. In glaucoma, anticholinergic effects can raise pressure inside the eye. In an enlarged prostate, they can make it even harder to empty the bladder.
Drug Interactions From Stacking Anticholinergics
One of the more practical reasons to know about meclizine’s anticholinergic properties is drug interactions. If you take meclizine alongside other medications that also block acetylcholine, the effects add up. This includes common over-the-counter drugs like diphenhydramine (Benadryl), certain sleep aids, older antidepressants, and medications for overactive bladder. The combined anticholinergic load can intensify drowsiness, confusion, dry mouth, and urinary retention beyond what either drug would cause alone.
Meclizine also acts as a central nervous system depressant, so pairing it with alcohol, sedatives, or opioids can amplify drowsiness and slow reaction times. This stacking effect is especially relevant for older adults, who tend to be more sensitive to both anticholinergic and sedative effects.
Long-Term Use and Brain Health
There’s growing concern about the cumulative effect of anticholinergic drugs on the brain over time. Meclizine carries an Anticholinergic Cognitive Burden (ACB) score of 3, which is the highest category on that scale and places it alongside drugs considered “definite” anticholinergics for the purpose of tracking cognitive risk.
A study of community-dwelling older adults found that long-term exposure to anticholinergic medications during midlife was associated with increased risk of Alzheimer’s disease and faster brain atrophy. The researchers observed a dose-response relationship: each additional point of cumulative anticholinergic exposure was linked to a 6% greater risk of developing Alzheimer’s or mild cognitive impairment. The brain regions most affected, including areas involved in memory and executive function, showed accelerated thinning in people with higher anticholinergic exposure.
This doesn’t mean taking meclizine for a bout of motion sickness will harm your brain. The concern is about sustained, repeated use over months or years. Occasional use for a boat trip or a vertigo episode is a very different exposure profile than daily use for chronic dizziness. If you find yourself reaching for meclizine regularly, that’s worth a conversation about alternatives that carry less anticholinergic burden.
Where Meclizine Fits on the Anticholinergic Spectrum
It helps to think of anticholinergic activity as a spectrum rather than a yes-or-no category. On one end, you have powerful anticholinergics like scopolamine and certain bladder medications that bind tightly to muscarinic receptors and produce strong, obvious effects. On the other end, you have drugs with barely measurable anticholinergic activity. Meclizine sits somewhere in the middle: its receptor binding is weak in lab measurements, but its clinical effects are real enough to earn a high ACB score and FDA-labeled cautions about glaucoma and prostate enlargement.
So the short answer is yes, meclizine has anticholinergic effects, even though it’s technically classified as an antihistamine. For most people using it occasionally, those effects are mild and manageable. The anticholinergic dimension matters most when you’re taking other medications with similar properties, when you have a condition that anticholinergics can worsen, or when use becomes frequent and long-term.